Autologous melanoma lysate/NY-ESO-1-pulsed autologous dendritic cell vaccine

{
  "id": "MLC-T-ONC-011691",
  "term": "Autologous melanoma lysate/NY-ESO-1-pulsed autologous dendritic cell vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with both a lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and a synthetic peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/NY-ESO-1-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody-mediated immune responses against melanoma cells, which may result in melanoma cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-melanoma-lysate-ny-eso-1-pulsed-autologous-dendritic-cell-vaccine/"
}